Shanghai Rendu Biotechnology Co

Shanghai Rendu Biotechnology Co Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Shanghai Rendu Biotechnology Co (688193.SS) as of Oct 18, 2026 is 222.13 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was -312.17 % — a change of -171.16% (higher).

Cash Conversion

222.13 %

YoY

-171.16%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Shanghai Rendu Biotechnology Co is 2025 222.13 % . Cash Conversion Rate (OCF/Net Income) of Shanghai Rendu Biotechnology Co was 2024 -312.17 % . It decreases by -171.16% higher compared to the previous year.

The Shanghai Rendu Biotechnology Co Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
7.41 CNY
Jan 1, 2019
365.46 CNY
Jan 1, 2020
150.89 CNY
Jan 1, 2021
84.25 CNY
Jan 1, 2022
-17.54 CNY
Jan 1, 2023
208.15 CNY
Jan 1, 2024
-312.17 CNY
Jan 1, 2025
222.13 CNY
The Shanghai Rendu Biotechnology Co Cash Conversion history
YEARCash ConversionYoY
222.13 %-171.16%
-312.17 %-249.97%
208.15 %-1,287.05%
-17.54 %-120.81%
84.25 %-44.16%
150.89 %-58.71%
365.46 %+4,833.44%
7.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Shanghai Rendu Biotechnology Co Stock analysis

What does Shanghai Rendu Biotechnology Co do? Shanghai Rendu Biotechnology Co Ltd develops molecular diagnostic tests using RNA isothermal amplification technology, offering reagents for respiratory, reproductive, enterovirus, and blood-borne disease diagnostics. Headquartered in Shanghai, China, the company employs 528 full-time staff and operates primarily within the domestic market. Listed on March 30, 2022, it designs and manufactures medical instruments alongside its diagnostic products. Shanghai Rendu Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Rendu Biotechnology Co stock

Cash Conversion Rate (OCF/Net Income) of Shanghai Rendu Biotechnology Co is 222.13 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Shanghai Rendu Biotechnology Co changed from -312.17 % to 222.13 %, representing a -171.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Shanghai Rendu Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Shanghai Rendu Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Shanghai Rendu Biotechnology Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Shanghai Rendu Biotechnology Co